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The earliest reports on the therapeutic use of the 
metals or metal-containing compounds in cancer and 
leukemia were dated back to 19th century. Until 1960s, 
the knowledge about mechanism of their antitumor 
activity was limited due to the technological restrictions 
and lack of scientific approach for their exploration. 
The discovery of the inorganic complex cis-diammine-
dichloroplatinum (II) (cisplatin) led to the develop-
ment of other types of non-organic cytostatic drugs 
for the treatment of tumors. Numerous other metal 
compounds that contained platinum, other platinum 
metals, and even non-platinum main group metals, in-
cluding tin, were then shown to be effective against tu-
mors. In the field of organometallic chemistry organo-
tin compounds shares a very important prospective. 
The organotin compounds or stannanes are chemical 
compounds based on the tin with hydrocarbon sub-
stituents. In recent years, organotin compounds have 
drawn much attention as antitumor agents [1–3]. The 
R2Sn(IV)
2+ compounds exhibit maximal antitumor ac-
tivity with low toxicity, are the type R2SnX2L2 (X = halo-
gen, pseudo halogen and L= O- or N-donor ligands) 
[4–7]. Diorganotin(IV) compounds, R2SnCl2 are often 
tetrahedral, and structurally similar with cisplatin. 
A large number of such complexes have been tested 
for antitumor activity [3, 8]. Investigations of thiosemi-
carbazone Sn(IV) complexes have been carried out 
by many researchers [2, 9, 10]. It has been observed 
that several di- and triorganotin(IV) species were ac-
tive against various types of cancer cells [5, 11]. The 
compounds usually realize their effect by interacting 
with the nucleic acid base [12]. A number of positive 
results have been reported in this direction [3, 7, 13]. 
Organotin compound has antiproliferative ability and 
antitumor activity on mammalian cells both in vitro and 
in vivo [3, 7, 8, 13]. Also, in Japan works regarding the 
immune response induced by implantation of tumor 
cells was further stimulated by D-fraction of Maitake 
mushroom have been carried out [14].
In the present study, we studied the potential anti-
tumor activity of a novel rationally designed compound 
dimethyl tin 4-cyclohexyl thiosemicarbazone (D4-t), 
which have ONS (oxygen/ nitrogen/sulphur) donors 
in its structure to develop an appropriate “bite angles”. 
The compound is expected to coordinate with DNA 
base pairs. The synthesis, lymphocyte activation and 
evaluation of D4-t anticancer activity were performed 
and discussed.
MATERIALS AND METHODS
Chemical synthesis. The ligand 4-cylohexyl 
thiosemicarbazone was prepared from cyclohexyl 
thiosemicarbazide and salicyl aldehyde as described 
[15]. Then methanol solution of dimethyltin dichloride 
and sodium hydroxide solution (50% excess) were 
mixed to prepare dimethyltin oxide [10, 16]. After that, 
condensation of dimethyltin oxide (1 M) and the ligand 
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(1 M) in benzene (100 ml) was performed by Dean 
Stark method for 8 h [10, 16]. The prepared D4-t was 
purified from pet ether and benzene.
IR spectroscopy (FTIR-8300-Shimadzu, KBR op-
tics using nujol mull) and 1H NMR spectra (1H NMR: 
Bruker 300-DPX, δ values, TMS as internal standard) 
of D4-t were measured. Release of radioactivity was 
counted in liquid scintillation counter (Model no. LKB 
1209 Rack-Beta).
In vivo screening. All in vivo experiments were 
conducted according to the rules and regulations 
of Committee for the Purpose of Control and Super-
vision of Experiments on Animals (CPCSEA), India. 
Sarcoma-180 (S-180) cells were obtained from the 
National Center for Cell Sciences (Pune, India) and 
maintained in Swiss albino male mice (6–7 weeks 
old, 24 ± 2 g) by intra peritoneal (i. p.) transplantation 
of 1.0 × 106 cells/0.2 ml physio logical saline/animal 
[17]. Mice were divided in groups as control (untreated), 
D4-t treated and ConA / Platin 10 treated. At least 6 ani-
mals were used for a particular group in an experiment. 
Physiological saline containing 0.2 ml of Freund’s in-
complete adjuvant (Sigma-Aldrich Chemicals Pvt. 
Ltd., India) was used as vehicle for drug administra-
tion by i.p. injection. Compounds in respective doses 
were administered to each mouse in treated groups 
as per the experiment performed. Group 1: The control 
groups received equal volumes of vehicle. Group 2: 
Mice treated with D4-t in respective doses through i.p. 
route. Group 3: Concanavalin A (ConA) (Sigma-Aldrich 
Chemicals Pvt. Ltd., India) dissolved in sterilized dis-
tilled water before intravenous (i. v.) injection was used 
as positive control. For evaluation of antitumor activity 
cisplatin injection (Platin10) (Cadila Pharmaceuticals 
Ltd., India) was used as positive control.
In vivo lymphocyte activation. The degree 
of activation by ConA of lymphocytes of secondary 
lymphoid organs and peripheral blood is considered 
as the measure of in vivo lymphocyte activation [18, 
19]. Mice were injected with three different doses 
of D4-t on day 0: 1 mg/kg, 5 mg/kg and 10 mg/kg 
of body wt of mice. Cell suspensions from different 
lymphoid organs such as spleen (SP), mesenteric 
lymph node (MLN) and other lymph nodes (LN) were 
prepared. The peripheral blood (PB) was on Ficoll and 
Hypaque solution (Sigma-Aldrich Chemicals Pvt. Ltd., 
India) for separation of lymphocytes [18, 19]. Then 
D4-t-stimulated blast transformation was measured. 
The dose of 50 µg of ConA in 0.1 ml/animal was chosen 
for lymphocyte activation. The rate of blast transforma-
tion of lymphocytes of lymphoid organs was recorded 
at 24 h up to 96 h [18].
The process of activation and blast transformation 
of lymphocytes were evaluated by the rate of DNA syn-
thesis, which was measured by the rate of 3H-thymidine 
incorporation into DNA. The optimal dose of ConA for 
DNA synthesis was 10 µg in 0.1 ml/animal [18]. So this 
dose was used in this case apart from using three dif-
ferent doses of D4-t injected on day 0. The assay was 
made at 24 h up to 96 h after injection. Cell suspen-
sions of SP were adjusted to 1.0 × 106 / 0.1 ml after 
the addition of 3H-thymidine (activity 10 µCi each) 
dissolved in 0.01 ml sterile saline. Using the standard 
method of incubation for 8 h followed by precipita-
tion with 10% chilled trichloroacetic acid, the release 
of radioactivity was recorded with the help of liquid 
scintillation counter [18, 20].
Evaluation of antitumor activity. S-180 tumor 
cells (1.0 × 106 cells/animal) were s. c. implanted 
in normal Swiss albino mice on day 0. At least 6 animals 
were used for a particular group, divided as cont-
rol (untreated) and treated (D4-t, ConA / Platin 10) 
in an experiment.
S-180 bearing animals treated with D4-t on day 
1 by i. p. route for this experiment (optimal dose 
of 5 mg/kg) were killed, their SP and MLN were iso-
lated at different time points after day 1 (24, 48, 72 and 
96 h), and fixed in Bouin’s fixative. Histological sec-
tions were made and stained with Delafield’s haema-
toxylin and eosin. The histopathological changes were 
evaluated by microscopy. In control, the experiments 
were performed without any drug injection and ConA 
was used as standard [21].
In Winn or tumor neutralization assay, D4-t (5 mg/kg 
dose by i. p.) and ConA (50 µg in 0.1 ml/ani mal by i. v.) 
were injected on day 1  after injecting S-180 on day 
0. Then on day 5, SP cell suspension from ConA and 
D4-t treated mice or S-180 bea ring control mice was 
mixed with S-180 tumor cells (1 : 1) and inoculated into 
normal mice. ConA treated, D4-t treated and control 
mice were weighed daily as described in [14].
To study the inhibitory effects of D4-t on DNA 
synthesis in S-180 in vitro 3H-thymidine incorporation 
assay was used as described in [22]. Tumor cells were 
removed at the 7th day after tumor transplantation, 
washed twice in Hank’s balanced salt solutions, re-
suspended in RPMI-1640 medium supplemented with 
10% heat inactivated fetal calf serum, streptomycin 
(100 µg/ml) and penicillin (100 units/ml), followed 
by viable cell count. To the cells (1.0 × 106/0.1 ml) with 
3H-thymidine (10 µCi each) D4-t was added at concen-
tration of 0.0016 µM and cells were incubated at 37 °C 
for 30 min and 60 min. As controls, the same concen-
trations of ConA and Platin10 were used.
Statistical analysis. Values were expressed 
as the mean ± SD. Experimental results were analyzed 
by Student’s t-test. P < 0.05 was considered as the 
level of significance for values obtained for treated 
groups, compared with the control group.
RESuLTS
The pathway of D4-t synthesis is presented 
on Fig. 1. Melting point (M. pt.) of D4-t was 97–98 °C. 
The yield of the dark yellow coloured solid compound 
was 80%. The calculated Carbon Hydrogen Nitro-
gen (CHN) percentage (%) was 45.3, 5.4, 9.9 and 
the observed CHN % was 44.8, 5.2, 9.1 respec-
tively. IR (cm–1) values was 1600 (CH=N), 968 (C-S), 
530 (Sn-O), 478 (Sn-C). 1H NMR (δ ppm, CDCl3) 
of D4-t was 0.85 (s, 6H, 2×CH3), 1.35 (m,11H,C6H11), 
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4.7 (d,1H,NH), 6.77 (m,2H, aromH), 7.1 (d,1H,aromH), 
7.26 (m,1H,aromH) and 8.6 (s,1H, CHN).
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fig. 1. The pathway of D4-t synthesis
In vivo activation of lymphocytes with different 
do ses of D4-t at different time intervals was exami-
ned. The dose wise effect of ConA is presented 
on Fig. 2, a. The dose wise effects of D4-t are presen-
ted on Fig. 2, b–d. The peak of blastogenesis of cells 
from all sources (SP, LN, MLN and PB) irrespective 
of D4-t dose was effectively reached at 72 h. The 
responses were almost at the same level in 24 h for 
all three studied D4-t doses. The blast cells became 
more vacuolated or exhausted at 72 h up to 96 h. The 
increase in the percentage of vacuolated cells corre-
sponded to the 10 mg/kg of D4-t (see Fig. 2, d). The 
significance of the difference between the groups 
(P < 0.01) was found.
Patterns of DNA synthesis by SP cells upon treat-
ment by D4-t and ConA are presented on Fig. 3. With 
all three studied D4-t doses, maximum incorpora-
tion of 3H-thymidine was observed at 48 h, and the 
index decreased between 48 h up to 96 h time points 
(P < 0.001). The rate of DNA synthesis was higher for 
5 mg/kg dose and almost reached the ConA value.
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fig. 3. Pattern of 3H-Thymidine incorporation by splenic lym-
phocytes at different time points after in vivo stimulation by ConA 
(10 µg) and D4-t (1 mg/kg, 5 mg/ kg, and 10 mg/ kg)
The in vivo antitumor activity of D4-t in S-180 was 
determined following the treatment of animals at the 
dose of 5 mg/kg.
In histological preparations of SP and MLN the 
gradual transformation of the lymphocytes into blasts 
was observed. Within 24 h of the treatment, SP cells 
of D4-t treated animals were loosely packed in com-
parison to control mice (S-180 bearing untreated 
mice). A higher percentage of blasts in MLN than 
in SP were recorded within 24 h. By 48 h most of the 
MLN cells differentiated into blast cells (data not 
presented).
In Winn assay the weight of tumor bearing mice, 
treated by D4-t increased from the day 1 to day 14, 
but after day 15 decreased compared with the weight 
of control animals and reached the value shown for 
ConA treated animals (Fig. 4). Significant regression 
(P < 0.01) was observed in mice inoculated with the 
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fig. 2. Kinetics of blastogenesis of lymphocytes treated by ConA at a dose of 50 µg in 0.1 ml/animal (a), by D4-t at a doses 
of 1 mg/kg body weight (b), of 5 mg/kg (c) and 10 mg/kg (d)
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mixture of tumor cells and SP cells obtained from 
D4-t pre-treated mice.
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fig. 4. Body weight changes of mice treated by D4-t, ConA and 
control mice in tumor neutralization assay (Winn assay)
To ascertain whether drug-induced tumor growth 
inhibition was achieved due to the inhibitory effect 
of D4-t on DNA synthesis, we performed DNA syn-
thesis assay. The untreated S-180 cells demonstrated 
an almost linear pattern of 3H-thymidine uptake over 
a period of 60 min (Fig. 5). Simultaneous exposure 
of tumor cells to 0.0016 µM D4-t resulted in gradual and 
marked inhibition of 3H-thymidine uptake (P < 0.001). 
The effect was almost equal to that in Platin10-treated 
cells, but greater than for ConA-treated cells. Thus, 
at the end of 60 min incubation Platin10, ConA and 
D4-t exhibited 95%, 66% and 80% of DNA synthesis 
inhibition compared with control untreated cells, re-
spectively (see Fig. 5).
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fig. 5. Effect of Platin10, D4-t and ConA on DNA synthesis 
by S-180 tumor cells
DISCuSSION
The evaluation of D4-t induced blastogenesis was 
the first criterion to get an idea whether D4-t could 
effectively induce blast transformation, and what 
are the optimal time interval and D4-t concentra-
tions. Blastogenesis is the culmination of several 
biochemical events, and affects almost every meta-
bolic pathway [23]. The blast cell count in the present 
investigation shows that D4-t can stimulate lymphoid 
system of mice in vivo and cause blast differen-
tiation of lymphocytes. As it was shown previously 
by others, ConA seems to be the best stimulating 
agent of the lymphocytes in vivo, with maximal effect 
at 48 h [18]. In comparison with ConA, and different 
examined D4-t doses (see Fig. 2, a–d), we found that 
5 mg/kg of D4-t showed greater degree of stimula-
tion of lymphocytes, as documented by high number 
of healthy blast cells without any sign of vacuolation 
or exhaustion. The optimal D4-t dose of 5 mg/kg was 
confirmed by duplicate screening experiments.
The DNA synthesis assay is also widely used for 
evaluation of lymphocytes activation in vivo [24]. The 
rate of DNA synthesis by the SP lymphocytes has been 
followed as the pattern of blastogenesis in current 
study. By conventional criteria the difference was con-
sidered to be very statistically significant (P < 0.001). 
It was previously shown that the optimal dose of ConA 
for the blastogenic responses of the lymphocytes did 
not correlate with DNA synthesis [18]. But as we have 
shown, in the case of D4-t the maximum rate of blas-
togenesis corresponded to the optimal D4-t dose and 
correlated with the rate of DNA synthesis.
Next, SP and MLN were isolated from the S-180 tu-
mor bearing mice, treated by 5 mg/kg dose of D4-t, 
and histological sections were studied. The loosely 
packed cells of SP possibly reflected the gradual trans-
formation of lymphocytes into blast cells. MLN cells 
are more sensitive to ConA treatment than SP cells, 
as it was observed on the histological sections of MLN 
and SP that most of the MLN cells differentiated into 
blasts by 48 h [21]. In current study the same effect 
was observed for the optimal dose of D4-t (data not 
presented). We didn’t observe any abnormalities 
of cells treated by D4-t at its optimal dose.
It was found that significant (P < 0.01) inhibition 
of tumor growth was in full agreement with the Winn as-
say data’s. In Winn assay tumor mass regression allow 
us to suggest the antitumor efficacy of D4-t without 
severe toxicity (see Fig. 4).
As D4-t showed 80% inhibition of 3H-thymidine 
uptake in comparison to Platin10 and ConA it can 
be concluded that D4-t could inhibit DNA synthesis 
of S-180 tumor cells (highly significant P < 0.001).
In conclusion, the above results indicate promi-
sing therapeutic potential of dimethyl tin 4-cyclohexyl 
thiosemicarbazone (D4-t).
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